Jim Simons Renaissance Technologies
Jim Simons is the founder of Renaissance Technologies, one of the most successful quantitative hedge funds in the world. Before his career in finance, he served as a mathematics professor and made significant contributions to differential geometry. Simons applied his analytical expertise to develop sophisticated, algorithm-driven trading strategies, earning consistently high returns for investors.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gilead Sciences
GILD
|
+$247M |
| 2 |
Johnson & Johnson
JNJ
|
+$225M |
| 3 |
MON
Monsanto Co
MON
|
+$213M |
| 4 |
AET
Aetna Inc
AET
|
+$208M |
| 5 |
Broadcom
AVGO
|
+$176M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$227M |
| 2 |
Microsoft
MSFT
|
+$224M |
| 3 |
Alphabet (Google) Class C
GOOG
|
+$205M |
| 4 |
Nike
NKE
|
+$187M |
| 5 |
Pfizer
PFE
|
+$184M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Financials | 14.12% |
| 2 | Technology | 12.96% |
| 3 | Healthcare | 12.08% |
| 4 | Industrials | 11.23% |
| 5 | Consumer Staples | 8.62% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
GNRT
2901
DELISTED
Gener8 Maritime, Inc.
GNRT
| $303K | ﹤0.01% |
+67,661
| New | +$302K |
|
2902
SemiLEDS
LEDS
$19.9M
| $302K | ﹤0.01% |
86,170
-40,300
| -32% | -$178K |
|
|
MVO
2903
DELISTED
MV Oil Trust
MVO
| $301K | ﹤0.01% |
+48,359
| New | +$285K |
|
2904
SIFCO Industries
SIF
$124M
| $301K | ﹤0.01% |
39,300
-2,000
| -5% | -$18.8K |
|
|
MCF
2905
DELISTED
Contango Oil & Gas Co.
MCF
| $300K | ﹤0.01% |
32,100
-18,300
| -36% | -$174K |
|
|
EDN
2906
Edenor
EDN
$994M
| $299K | ﹤0.01% |
10,745
-353
| -3% | -$8.94K |
|
2907
Apollo Global Management
APO
$81.9B
| $297K | ﹤0.01% |
+15,334
| New | +$290K |
|
2908
Professional Diversity Network
IPDN
$3.06M
| $297K | ﹤0.01% |
+1,362
| New | +$216K |
|
2909
Urban One Class A
UONE
$23.3M
| $297K | ﹤0.01% |
10,060
+10
| +0.1% | +$279 |
|
|
SMTX
2910
DELISTED
SMTC Corporation
SMTX
| $297K | ﹤0.01% |
194,100
+23,000
| +13% | +$32.3K |
|
|
ABAC
2911
DELISTED
Renmin Tianli Group, Inc. Common Shares
ABAC
| $297K | ﹤0.01% |
82,175
+10,900
| +15% | +$31.3K |
|
2912
Douglas Dynamics
PLOW
$981M
| $296K | ﹤0.01% |
8,800
-144,303
| -94% | -$4.59M |
|
|
STRM
2913
DELISTED
Streamline Health Solutions
STRM
| $296K | ﹤0.01% |
15,780
+2,420
| +18% | +$60.6K |
|
|
BPMC
2914
DELISTED
Blueprint Medicines
BPMC
| $295K | ﹤0.01% |
10,500
-700
| -6% | -$21.1K |
|
2915
Mind CTI
MNDO
$20.6M
| $295K | ﹤0.01% |
119,900
-9,000
| -7% | -$21.2K |
|
2916
vTv Therapeutics
VTVT
$125M
| $294K | ﹤0.01% |
1,523
+298
| +24% | +$68.5K |
|
2917
Value Line
VALU
$360M
| $293K | ﹤0.01% |
15,000
+400
| +3% | +$7.82K |
|
2918
iRadimed
IRMD
$1.12B
| $292K | ﹤0.01% |
26,300
-19,600
| -43% | -$211K |
|
|
IDXG
2919
DELISTED
Interpace Biosciences, Inc. Common Stock
IDXG
| $292K | ﹤0.01% |
6,642
-209
| -3% | -$6.66K |
|
2920
Moog Inc Class B
MOG.B
$13B
| $291K | ﹤0.01% |
4,400
+200
| +5% | +$12.8K |
|
2921
Axcelis
ACLS
$4.39B
| $290K | ﹤0.01% |
19,950
-100,399
| -83% | -$1.37M |
|
2922
Intellicheck
IDN
$75.9M
| $287K | ﹤0.01% |
104,200
+59,700
| +134% | +$130K |
|
|
NGHC
2923
DELISTED
National General Holdings Corp
NGHC
| $287K | ﹤0.01% |
11,500
-104,900
| -90% | -$2.38M |
|
|
CNV
2924
DELISTED
CNOVA N.V.
CNV
| $284K | ﹤0.01% |
+51,800
| New | +$282K |
|
|
CBR
2925
DELISTED
CIBER Inc.
CBR
| $283K | ﹤0.01% |
447,700
+105,000
| +31% | +$90.4K |
|
Similar funds
Jim Simons's Q4 2016 Portfolio in Review
As of Q4 2016, Jim Simons held 3,715 positions worth $63.2B, up 12% from $56.6B the previous quarter. Its ten largest holdings account for 7.2% of the portfolio.
Jim Simons deployed $5.07B of net new capital in Q4 2016, opening 418 new positions and adding to 1,792 existing holdings. Its largest new stake was Broadcom: 10,144,960 shares worth $179M.
By sector, the portfolio is most concentrated in Financials at 14% of assets, up from 12% a quarter earlier, followed by Technology and Healthcare.
On the sell side, the largest reduction was Bristol-Myers Squibb, an estimated $227M trimmed.
- Jim Simons's largest Q4 2016 buy was Broadcom: 10,144,960 shares worth $179M.
- Jim Simons added most to Gilead Sciences in Q4 2016, an estimated $247M increase.
- Jim Simons's biggest Q4 2016 reduction was Bristol-Myers Squibb, cutting an estimated $227M.
- Jim Simons fully exited Alphabet (Google) Class C in Q4 2016, selling an estimated $205M.
- Jim Simons's ten largest holdings make up 7.2% of its $63.2B portfolio in Q4 2016.
- Jim Simons opened 418 new positions and closed 494 in Q4 2016.
- Jim Simons's portfolio value rose 12% quarter-over-quarter to $63.2B.
Based on Renaissance Technologies's 13F filing for Q4 2016, filed 13 Feb 2017.